Parry Romberg Syndrome

Secukinumab treatment of Parry-Romberg syndrome

“… 3 Atrophy can continue intraorally, affecting dentition and tongue, whereas trunk and limb involvement are rarely reported. 2 , 4 Bilateral cases are less common. Onset usually occurs before aged 20 years, more commonly in female individuals, with true incidence unknown.…”

“…Disease self-stabilization usually occurs within 2 to 10 years, but slow atrophy progression until then causes functional and aesthetic changes that can affect the patient both physically and psychosocially. 2 , 4 Greater repercussions can occur with earlier age of onset because of the effect on facial development. 4 Extra–soft tissue manifestations include facial pain, headache, seizures, enophthalmos, and uveitis, as well as possible rheumatologic, cardiac, or endocrine changes.…”

“… 2 , 4 Greater repercussions can occur with earlier age of onset because of the effect on facial development. 4 Extra–soft tissue manifestations include facial pain, headache, seizures, enophthalmos, and uveitis, as well as possible rheumatologic, cardiac, or endocrine changes. 1 , 2 Diagnosis is clinical.…”

“… 2 In mild defects, synthetic fillers such as hyaluronic acid can be used but require repetitive treatments and risk migration, foreign body reaction, or increased resorption compared with lipofilling. 4 Serial lipofilling is therefore preferred in mild to moderate defects, and can be used in conjunction with skeletal and soft tissue augmentation in more severe cases. 2 , 4 Systemic therapy to halt disease progress earlier is advised.…”

“… 4 Serial lipofilling is therefore preferred in mild to moderate defects, and can be used in conjunction with skeletal and soft tissue augmentation in more severe cases. 2 , 4 Systemic therapy to halt disease progress earlier is advised. 3 Methotrexate, systemic corticosteroids, mycophenolate mofetil, cyclosporine, azathioprine, and hydroxychloroquine have been used, with variable success.…”